Public Sector Biomanufacturing & Institutional CDMO Support
CDMO Network is the CDMO for public sector, institutional, academic, nonprofit, and mission-driven biomanufacturing programs that need structured execution across science, quality, procurement, and supply.
Public programs do not move like standard biotech programs. They carry public accountability, grant timelines, agency priorities, procurement rules, academic milestones, nonprofit funding limits, and multi-stakeholder oversight. The work needs more than capacity. It needs a manufacturing route that is technically sound, financially clear, quality-aligned, and documentation-ready.
Support spans biologics development, process development, GMP readiness, clinical supply, vaccine manufacturing, viral vectors, recombinant proteins, antibodies, enzymes, plasmids, diagnostic components, microbiome products, research reagents, formulation, stability, fill-finish, quality systems, tech transfer, and supply chain coordination.
Best fit
- Government biologics and public health programs
- Academic translational manufacturing
- Institutional GMP readiness
- Public-private biomanufacturing partnerships
- Grant-funded and nonprofit therapeutic programs
- Pandemic preparedness and emergency response manufacturing
- Vaccine, diagnostic, vector, protein, plasmid, microbiome, and advanced biologics programs
- Multi-stakeholder programs requiring CDMO selection, quality oversight, and supply coordination
Structured execution for public programs
Public sector biomanufacturing starts with a mission. A government agency may need vaccine capacity. A university may need translational manufacturing for a promising biologic. A nonprofit may need affordable clinical supply. A public-private partnership may need several providers coordinated across drug substance, fill-finish, QC testing, stability, and distribution.
The route should fit the product, stage, quality level, funding model, procurement pathway, timeline, and intended use. A grant-funded feasibility program needs a different route than a national preparedness initiative. An academic protein project needs a different model than a public-sector viral vector program.
The goal is simple: define the right manufacturing path before time, money, and material are committed.
Government and agency-supported programs
Government-supported programs need transparent vendor rationale, documented quality expectations, reliable reporting, and clear deliverables.
Support includes technical intake, CDMO selection, RFP strategy, feasibility manufacturing, process development, analytical testing, GMP manufacturing, fill-finish, stability planning, regulatory CMC, quality system review, supplier qualification, tech transfer, and supply chain planning.
Every CDMO decision must stand up to scientific, procurement, legal, program, and public review. Availability is not enough. The provider must fit the modality, stage, scale, quality level, timeline, and risk profile.
Academic translational manufacturing
Academic programs often have strong science before they have a manufacturing route.
Support helps universities and translational teams move from research material to controlled development material, GMP-adjacent production, or GMP-ready manufacturing.
The work includes construct review, host selection, expression screening, process feasibility, purification development, analytical testing, formulation, stability planning, GMP gap assessment, tech transfer planning, and batch documentation.
Academic programs need enough manufacturing clarity to support grants, partnerships, licensing, IND-enabling work, institutional review, and spinout formation.
Public-private partnerships
Public-private partnerships require coordination across agencies, universities, sponsors, CDMOs, testing labs, nonprofits, and regulatory teams.
A strong route defines partner responsibilities, CDMO roles, quality expectations, reporting structure, transfer points, decision gates, risk registers, and program milestones.
These programs should not depend on informal alignment. Every stakeholder needs to know what happens next, who owns it, and what evidence supports the decision.
Pandemic preparedness and public health manufacturing
Preparedness programs need speed without losing control.
Support includes vaccine antigen production, viral vector manufacturing, mRNA and plasmid support, diagnostic reagent supply, enzyme production, recombinant protein production, fill-finish, stability planning, cold-chain logistics, quality review, tech transfer, and emergency supply coordination.
Preparedness is not just capacity. It is readiness across process, testing, quality, documentation, storage, packaging, and distribution.
Grant-funded and nonprofit programs
Grant-funded and nonprofit programs need disciplined scope control.
Support includes scope design, proposal-ready technical planning, CDMO comparison, phased manufacturing plans, budget-sensitive process development, analytical gap review, GMP readiness, batch planning, stability design, and documentation support.
The work must answer the next technical question without overspending on studies, methods, or infrastructure that the current milestone does not require.
Institutional GMP readiness
Research systems do not automatically become regulated manufacturing systems.
Institutional GMP readiness includes raw material controls, batch records, sampling plans, analytical methods, specifications, quality agreements, deviation pathways, release testing, supplier qualification, document control, training, equipment suitability, environmental monitoring, and quality review.
Some programs need full GMP. Others need GMP-adjacent documentation, ISO-aligned systems, diagnostic-quality controls, or controlled non-GMP development material. The intended use defines the quality level.
Modalities supported
Programs are supported across monoclonal antibodies, recombinant proteins, enzymes, viral vectors, plasmid DNA, mRNA, vaccine antigens, protein subunits, viral vector vaccines, live biotherapeutics, microbiome products, diagnostic reagents, research tools, cell therapy materials, engineered microbes, phage, nanoparticles, and hybrid biological platforms.
Each product needs a specific route.
Vaccine programs need antigen, potency, formulation, fill-finish, and distribution planning. Diagnostic reagent programs need lot consistency, assay performance, and scalable supply. Viral vector programs need plasmid control, producer systems, functional titer, impurity testing, and frozen logistics. Recombinant protein programs need expression, purification, activity, formulation, and stability. Microbiome programs need strain identity, viability, fermentation, formulation, and storage control.
Quality, reporting, and documentation
Documentation belongs inside the program route, not at the end.
The work includes batch records, COAs, analytical reports, stability data, method summaries, raw material documentation, supplier records, quality agreements, deviation summaries, change control records, milestone reports, grant deliverables, audit files, regulatory source documents, and procurement documentation.
Documentation protects accountability. It gives scientific, procurement, funding, regulatory, and governance teams a shared record of what was done, why it was done, and what evidence supports the next step.
Procurement and CDMO selection
Institutional procurement requires more than a price comparison.
Support includes capability mapping, vendor comparison, proposal review, scope clarification, technical scoring, risk assessment, timeline review, and documentation of fit.
A low-cost bid may exclude analytical development, stability, quality review, raw materials, tech transfer, or regulatory documentation. A high-capacity CDMO may still be wrong for a niche modality. A local provider may help with geography but fail technical fit.
CDMO selection works when technical fit, procurement requirements, budget, quality expectations, and future development needs are evaluated together.
Supply chain and logistics
Public programs move material across academic labs, government sites, CDMOs, testing labs, clinical centers, and storage depots.
Support includes material planning, supplier qualification, cold-chain coordination, inventory strategy, shipment qualification, chain of custody, import and export planning, storage, labeling, packaging, clinical supply coordination, and excursion response.
A strong logistics plan protects product quality, documentation, ownership, and program continuity.
CDMO Network is ready to help!
Public sector and institutional biomanufacturing programs need a CDMO route that fits the mission, product, funding structure, quality level, procurement pathway, stakeholder model, and supply goal.
CDMO Network supports that full route from technical intake and CDMO selection through development, GMP readiness, manufacturing, testing, documentation, tech transfer, logistics, and clinical supply coordination.
Email our team at info@cdmonetwork.com